Navigation Links
Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure
Date:1/8/2008

SAN MATEO, Calif., Jan. 8 /PRNewswire/ -- Corthera Inc. today announced the initiation of patient enrollment in a Phase II clinical trial of Relaxin, a naturally occurring peptide hormone that is being developed for acute heart failure and other acute care illnesses.

The trial will investigate the efficacy and safety of Relaxin in patients with acute heart failure. Approximately 330 patients will be recruited from more than 50 investigational centers worldwide. The primary outcome measure is the improvement of clinical signs and symptoms of acute heart failure, with additional secondary outcome measures, including improvement in renal function.

"With the current lack of safe and effective therapies for acute heart failure, we are very pleased to advance the development of Relaxin for the benefit of these patients," said Stan E. Abel, president and chief executive officer of Corthera. "The clinical and preclinical results to date are very encouraging, demonstrating Relaxin's beneficial hemodynamic properties."

According to the American Heart Association, heart failure is a costly cardiac and renal syndrome affecting more than 550,000 new patients per year, with projected direct and indirect costs at $33.2 billion in 2007. Acute heart failure is characterized by fluid overload (congestion), especially in the lungs, that causes shortness of breath and other complications. The current standard of care includes diuretics and vasodilators. Diuretics, which promote fluid excretion, are associated with renal complications. Vasodilators tested to date have been linked to hypotension, renal impairment and adverse outcomes.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a targeted vasodilator with demonstrated systemic and renal hemodynamic effects. Elevated levels of Relaxin are thought to modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent
'/>"/>

SOURCE Corthera Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
2. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
3. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
4. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
5. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
6. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
7. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
8. Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
9. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today ... Logo - ... "Our new corporate identity signifies our transformation into ... first predictive analytics platform for patent claim validity." ... launch of the proprietary AIA Shield™ platform, the Company commenced ...
(Date:8/28/2015)... and PITTSBURGH , Aug. 28, ... today announced that its shareholders have approved Mylan,s ... PRGO ; TASE) and the related issuance of ... extraordinary general meeting of shareholders held today. The ... at the extraordinary general meeting. In addition, the ...
(Date:8/28/2015)... ANDOVER, Massachusetts and LONDON , ... driven approach seamlessly ... health continuum improving outcomes and ... Philips  (NYSE: PHG AEX: PHIA) today announced its presence ... its latest cardiology solutions, including Heart Model A.I. , EchoNavigator ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... are adulterated and misbranded; safety and efficacy not established , ... SILVER SPRING, ... the U.S. Food and Drug Administration, U.S. Marshals today seized ... Quality Monitor devices, as well as component parts used in the ...
... July 27 Volcano Corporation (Nasdaq: VOLC ) stated today ... it by St. Jude Medical in federal district court in Delaware ... and looks forward to vindicating its rights in court. , ... The Complaint filed today has nothing ...
Cached Medicine Technology:Federal Agents Seize FastSize Extenders and FastSize EQM™ Erectile Quality Monitors 2Volcano Will Strongly Defend Against St. Jude Lawsuit 2Volcano Will Strongly Defend Against St. Jude Lawsuit 3
(Date:8/28/2015)... , ... August 28, 2015 , ... An article ... local pizza maker Paul LaRocco has gone through to open a pizzeria in Westchester. ... permitting process tends to take several months, but the current process, having already gone ...
(Date:8/28/2015)... , ... August 28, 2015 , ... As reported ... Merz, received FDA clearance for results that last for two years, the longest ... news for patients who are looking for a long-lasting, effective solution for their cellulite, ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, ... fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch ... CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected ...
(Date:8/28/2015)... Neb. (PRWEB) , ... August 28, 2015 , ... Medical ... the 2015 Best Places to Work in Healthcare by Modern Healthcare and ... , Now in its eighth year, the Best Places to Work in ...
(Date:8/28/2015)... ... 2015 , ... SmartPractice Calendars afford dental offices ... contact information and logos, Calendars stand alone as functional brand-building giveaways ... mailings, thank you and welcome communications, and to complement statements and invoices. 2016 ...
Breaking Medicine News(10 mins):Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2
... threat, even without diet changes, study finds , , MONDAY, Dec. ... of the week is enough to undo metabolic syndrome, a ... stroke, a new study suggests. , "What we found was ... in improving metabolic syndrome risk," said study author Johanna L. ...
... researcher showed that acute and chronic constipation together accounted for ... children treated at one hospital. , The study also suggests ... when trying to determine the cause of abdominal pain in ... 962 children ages 4 to nearly 18, appear in the ...
... cardiac safety, TAMPA, Fla., Dec. 17 ... in electro-stun technology, today,announced a major research university ... Systems, S-200 projectile stun gun. Details of the,study ... meeting and/or,in a scientific journal. However, this study ...
... an effort to,help prepare today,s students to ... United Nations Environment Programme,s North,American Regional Office ... Day partnership and launched the International Children,s,Painting ... The International Children,s Painting Competition (ICPC) invites,elementary ...
... the nation in percentage of diabetes patients receiving,recommended ... claims, DALLAS, Dec. 17 The Dallas-Fort ... release of a new report on the,prevalence, costs ... 2 diabetes. The,Texas Type 2 Diabetes Report 2007 ...
... ATLANTA, December 17, 2007A new American Cancer Society report ... cancer cases and 7.6 million cancer deaths (about 20,000 ... comes from the first-ever Global Cancer Facts & Figures, ... of Facts & Figures publications. The report estimates that ...
Cached Medicine News:Health News:Moderate Exercise Cuts Risk of Metabolic Syndrome 2Health News:Moderate Exercise Cuts Risk of Metabolic Syndrome 3Health News:Constipation most common cause of children's abdominal pain 2Health News:Medical Study of Stinger S-200 Stun Gun Completed 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Northern New Jersey Elementary and Middle Schools 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Northern New Jersey Elementary and Middle Schools 3Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Northern New Jersey Elementary and Middle Schools 4Health News:Dallas-Fort Worth Business Group on Health Releases Report on the State of Diabetes in Texas 2Health News:Dallas-Fort Worth Business Group on Health Releases Report on the State of Diabetes in Texas 3Health News:New report estimates 12 million cancer cases worldwide 2
The only ergonomic work station of its kind with an optional built-in keratograph and flat-screen. The Concepta is a modern workstation for the examination and refraction of patients....
The natural look of 3 in 1 technology in virtually any prescription....
Dot matrix pattern for light eyed patients....
Natural eye color change for even the darkest of eyes....
Medicine Products: